$GILD ELLIOTWAVES$GILD is looking bullish going into 2021
We need a breakout of this downtrend channel for the impulsive waves to be valid, look for a break at the red trendline as well as a retest as support in wave 4
Biotech
ObsEva, emerging company on verge of phase 3 completion
Hi Ya'll,
I hope you're having a Good Friday night. I came across this gem yesterday and I have to give it a shout out. ObsEva is a unique company, and has lots of potential. They have three drugs currently in pipelines. Its recently broken out and is channeling upward and moving very healthily. I have a price target of $10+. With a long term hold.
Yselty- Phase 3
Ebopripant - Phase 2
Nolasiban -Phase 1
www.obseva.com
Yselty is about to be finished testing. It looks positive and ready to be sold world wide. This product is very good for dealing with uterary fibroids which is very common and has no clear medication to use to solve it.
If y'all can post your own understanding of the significance of these drugs I would appreciate it. I do not fully understand what these drugs do but they seem to be a big deal.
Many analysts have set price targets ranging from $4.00-$28.00 a share.
I will link this.
www.tipranks.com
Please give the company corporate presentation a look, and please tell me if I missed anything crucial, like the executives, etc..
www.obseva.com
Thanks,
Benjamin
$MRK ELLIOTWAVESMy current waves on $MRK
would love some feedback, this catalyst and original chart was brought up originally by @tomikazi
It broke out of the downtrend channel and now is in wave 1.
Has a catalyst on Wednesday 1/20/21
PDUFA VII Decision for MRK's Vericiguat:
Merck Seeks Approval For Heart Failure Drug
Company: Merck & Co., Inc. (NYSE: MRK)
Type of Application: NDA
Candidate: vericiguat
Indication: heart failure
Positive ER expected :
Merck & Co., Inc.'s earnings, with the lowest EPS estimate coming in at $1.32 and the highest estimate coming in at $1.38. Merck & Co., Inc. reported
earnings of $1.16 per share during the same quarter last year, which indicates a positive year over year growth rate of 16.4%. The firm is scheduled to issue
its next quarterly earnings report before the market opens on Thursday, February 4th. -Marketbeat
LEXX -- Biotech play trading below just closed $5.25 financing$13.2M mkt cap, 3.5M float. Freshly uplisted to NASDAQ. Closed $11M oversubscribed financing at $5.25 on January 14th and trading at discount at $4.40. Oversold on the daily (RSI @ 28). Accum/Dist is evening out after 3 days of selloff. Gap at 6.41. Cash + assets exceed current market cap.
BLUE - Good Buying Opportunity With 3.42B Market Cap Bluebird Bio after four years again on good level to Buy, Profit Target Primary 70-80 and secondary is 100-140.
You can take this stock from short term to long term.
High probability swing short set up on CRSPHere is my short case on CRSP:
- at the top of trading channel started since Feb 2020
- over bought reading on RSI
- both PPO and RSI shows very clear divergence high
Starting building a position as it hits the top of the channel and scale in as it moves down. Impulsive break of the wedge should move it down to the support at $161. Reaction will be likely, consolidation or a minor bounce. Then, if it gets taken down, then moving down to the bottom of the channel which intersects with $145.80 horizontal support. If that breaks, it's going way lower since $110 and $131 area are pretty thin so the move will be probably pretty swift.
Full Commercial Launch of Tigereye(TM) Image-Guided CTO CrossingAvinger Initiates Full Commercial Launch of Tigereye(TM) Image-Guided CTO Crossing Catheter
With the initiation of full commercial launch, current and prospective accounts throughout the US and Germany are now able to order the Tigereye device.
During the fourth quarter of 2020, Avinger conducted a limited launch at 12 clinical centers in the U.S. and Germany. Approximately 50 CTO cases were successfully performed, showcasing Tigereye's advanced clinical capabilities and excellent product reliability in a variety of lesion types and settings.
The limited launch program demonstrated Tigereye's strong clinical results and efficiency across a wide range of PAD cases
"We believe full commercial availability of the Tigereye device will be an important contributor to expanding our revenue growth opportunities in 2021, both in terms of attracting new Avinger user sites and supporting higher utilization per site,"
finance.yahoo.com
FDA Emergency Use Authorization for SARS-CoV-2 N Protein AntigenQuanterix Receives FDA Emergency Use Authorization for SARS-CoV-2 N Protein Antigen Test
As case counts and positivity rates rise globally, the COVID-19 testing landscape is of critical importance
finance.yahoo.com
Sale of Manufacturing Operations and Global Supply AgreementAcorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement for INBRIJA®, Corporate Restructuring, and Enters into "At The Market" Offering Agreement
$80 million up-front payment will substantially increase cash balance
Sale, restructuring and other operating expense reductions will reduce annual operating expenses by approximately $40 million
Total 2021 non-GAAP operating expense guidance expected to be $130-$140 million1
At The Market (ATM) offering allows the sale of common stock at aggregate value up to $15.25 million
Supply agreement will ensure uninterrupted supply of INBRIJA (levodopa inhalation powder) to people with Parkinson’s
finance.yahoo.com stock
Biomerica’s Covid-19 Antigen Rapid Test Receives CE MarkBiomerica’s Fast 15-Minute Simple to Use Covid-19 Antigen Rapid Test Receives CE Mark
Biomerica receives first orders and plans to ship tests in coming weeks
Clinical studies demonstrated an overall performance of 94.7% positive agreement (sensitivity) and 99.7% negative agreement (specificity) as compared to lab-based molecular PCR tests
The Company has already received its first European orders and plans to ship the first part of these orders in the coming weeks. The Company will now begin marketing this product broadly in Europe and other regions outside of the US.
merica’s new COVID-19 Antigen Rapid Test is highly portable, affordable, and provides results in 15 minutes with no equipment required to perform or read the test.
finance.yahoo.com
BIOLASE Announces Agreement With DSO Dental Care AllianceBIOLASE Announces Agreement With DSO Dental Care Alliance To Expand Laser Adoption In Dental Offices Across The United States
BIOL announced an agreement with Dental Care Alliance (DCA), one of the largest dental support organizations (DSO) in the United States with more than 330 affiliated practices in 20 states, to expand laser adoption and hands-on training programs in targeted geographies. The Company expects the agreement to lead to a rollout across all DCA offices in 2021.
finance.yahoo.com
This NCNA Penny Stock Could Surge Over 300%, Say AnalystThis NCNA Penny Stock Could Surge Over 300%, Say Analyst
NuCana uses a phosphoramidate chemistry technology called ProTide to create a class of drugs that will surmount the limitations of the existing nucleotide analogs behind many chemotherapy drugs. NuCana’s ProTides have already been used in Gilead’s antiviral drug Sovaldi.
In May of last year, NuCana announced the restart of its Phase III trial on Acelarin, the drug candidate furthest along the company’s pipeline, as a treatment for biliary tract cancers. The study encompasses over 800 patients in 6 countries and is currently ongoing. In November, the company published data described as ‘encouraging’ from the Phase Ib study of the same drug.
While Acelarin is the flagship drug in the pipeline, NuCana has two other prospects under development. NUC-3373 is in Phase I trial as a treatment for solid tumors and colorectal cancers, and NUC-7738 is a second pathway under investigation for applications to advanced solid tumors. Of these three, the colorectal study is the farthest advanced.
5-star analyst Robyn Karnauskas sees the pipeline as key to NuCana’s investor potential.
“We believe investors have overlooked the fact that NCNA is a platform Company that we believe is validated, as defined by the production of clinical products. We like that it has brought 3 products to the clinic, including one novel drug and two improved cornerstone chemos. The data suggest to us that the platform works and can produce better chemos While investors are mostly focused on Acelarin, we believe investors should also focus on NUC-3373, another core to our platform-based thesis that has data expected in 1H2021,” Karnauskas noted.
To this end, Karnauskas puts a $22 price target on NCNA, suggesting the stock has room for 384% growth ahead of it, along with a Buy rating.
finance.yahoo.com
This ACRX Penny Stock Could Surge Over 300%, Say AnalystsThis ACRX Penny Stock Could Surge Over 300%, Say Analysts
AcelRx is a pharmaceutical company dedicated to the creation of safer treatments for acute pain, developing synthetic opioid drugs for sublingual (under the tongue) dosing.
The company’s main product, Sufentanil, was approved by the FDA under the name Dsuvia in 2018, and by the EU as Dzuveo that same year. A second sublingual Sufentanil system, under the name Zalviso, has also been approved for use by the EU, and is in Phase 3 trial in the US.
In its most recent earning report, the company showed $1.4 million at the top line, driven by $1.3 million in product sales. The sales figure was up 433% sequentially, and the total revenue figure was up 133% year-over-year.
Cantor analyst Brandon Folkes is upbeat on Dsuvia’s prospects as an alternative to current opioid treatments, and he believes that potential will boost the company’s stock.
As ACRX launches a true alternative to IV opioids, we expect investors to begin to appreciate the value of the product.
In line with his bullish stance, Folkes rates ACRX a Buy, and his $9 price target implies room for a stunning 552% upside potential in the next 12 months.
finance.yahoo.com
T2SARS-CoV-2™ Panel can detect multiple variants of the SARS-CoVT2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus
Panel can detect multiple variants of the SARS-CoV-2 virus, including those most recently identified in the United Kingdom, South Africa, and the U.S.
T2SARS-CoV-2 Panel, which has demonstrated clinical sensitivity of 95 percent and specificity of 100 percent.
The T2SARS-CoV-2 Panel provides results in under two hours utilizing an upper respiratory swab sample. The test runs on the Company’s FDA-cleared and fully-automated T2Dx® Instrument, which is capable of performing seven tests simultaneously and up to sixty samples per day.
finance.yahoo.com
Exclusive Licensing Agreement for GIAPREZA and XERAVA in EuropeLa Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe
La Jolla to receive upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments
Under the terms of the exclusive licensing agreement, La Jolla will be entitled to receive: (i) an upfront cash payment of $22.5 million; (ii) potential commercial milestone payments of up to $109.5 million; and (iii) double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA. In exchange, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories.
finance.yahoo.com
Stock to watch: Veru Inc (NASDAQ: VERU)NASDAQ:VERU
An interesting stock to watch.
The asset is in a 1,5 month uptrend without major pullbacks + MACD Crossover indicator's Long signal is still in progress.
The buy zone is marked out, targets are 12.5, 15, 18, 23,88 and towards the all-time high.
Invalidation: closing below the gap.
Disclaimer: This article should not be considered as financial or investment advice. Trading digital assets involve risk and may resolve in the loss of your capital. Always be sure to understand the amount of risk involved and do your research before taking any trading/investment steps.
Overextended to the downside, Corrective IMPULSE is DUE! (TMBR)Here is a low float pharmaceutical company with a hot bargain of a deal!
We currently sit on a very special only once every couple of years type of moment. MAJOR structural support is being tapped right now from a 7 year decline!
Pharmaceutical and Biotech sector look HOT and READY!
I'm starting to think a 4x move ain't so crazy.
I think it looks like a good long term play.
Day Traders Lighting Up Reddit Spur Rally in ZomedicaDay Traders Lighting Up Reddit Spur Rally in Tiny Health Stock Zomedica
Such outsized moves in small-caps are becoming par for the course these days.
Surging at the open on the back of mentions in Reddit forums was Zomedica Corp., a company that develops medicines for pets. The stock jumped as much as 98% on Monday and is up almost four-fold from the start or the year.
The penny stock garnered a mention in several Reddit forums over the past few days
finance.yahoo.com
Day Traders Lighting Up Reddit Spur Rally in TransEnterixDay Traders Lighting Up Reddit Spur Rally in Tiny Health Stock TRXC
The stock has surged about 180% since the start of the new year. Today’s trading volume was more than 13 times normal. The penny stock garnered a mention in several Reddit forums over the past few days, with one user comparing it with the roughly $95 billion market-cap leader in surgical robotics, Intuitive Surgical Inc.
TransEnterix markets the Senhance surgical system, cleared by the U.S. Food and Drug Administration in 2017. According to the device-maker in an update last week, 10 of the systems were installed in 2020. The Morrisville, North Carolina-based company said it ended 2020 with $17.5 million in cash and equivalents, enough to keep the company afloat into the third quarter.
finance.yahoo.com
GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine DevelopmentGeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development
announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a Small Business Innovative Research (SBIR) grant in support of its development of a vaccine against SARS-CoV-2, the virus that causes COVID-19.
The Phase 1 grant, titled, “Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19,” will support the ongoing design, construction and preclinical testing of GeoVax’s vaccine candidates in preparation for human clinical trials. The efficacy testing will be performed in collaboration with the University of Texas Medical Branch (UTMB).
Vaccines using the GV-MVA-VLP platform developed for other pathogens have proven to be efficacious with a single dose, having strong durability which would be a significant advantage for SARS-CoV-2 global vaccination campaigns.”
We are pleased to receive this Phase 1 SBIR funding award, which will supplement the internal resources allocated to our COVID-19 vaccine program and accelerate our progress toward human clinical trials.
finance.yahoo.com
Reduction in Heart Attacks, Strokes and Cardiac DeathSingle Dose of Rexlemestrocel-L Provides Substantial and Durable Reduction in Heart Attacks, Strokes and Cardiac Death in Patients With Chronic Heart Failure
results from the landmark DREAM-HF randomized controlled Phase 3 trial in 537 treated patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF) who received rexlemestrocel-L (REVASCOR®) or control sham.
A single dose of rexlemestrocel-L resulted in substantial and durable reductions in heart attacks, strokes, and cardiac deaths.
The incidence of heart attacks and strokes were reduced by 60% over a median follow-up period of 30 months following a single dose of rexlemestrocel-L in the population of 537 patients with New York Heart Association (NYHA) class II or III chronic heart failure (5% vs 13%, p=0.002).
The incidence of death from cardiovascular causes was reduced by 60% following a single dose of rexlemestrocel-L in the 206 patients with NYHA class II disease (8% vs 20%, p=0.037)
finance.yahoo.com
